Viral Vector and Plasmid DNA: Technologies and Global Markets

Description

List of Tables

The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.

The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.

The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

93 data tables and 47 additional tables
An overview of the global market for viral vector and plasmid DNA
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
A look at the innovations, technological advances, and product launches from leading companies
Analysis of the industry's regulatory framework and policies, and its product pipeline
Discussion of ESG challenges and ESG practices
Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
Profiles of the leading players in the industry

Product Code: BIO192B

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Viral Technology
Cell and Gene Therapy

Chapter 3 Market Dynamics

Market Dynamics
Drivers
Opportunities
Restraints
Challenges

Chapter 4 Emerging Technologies and Developments

Overview
AI in Viral Vector Production
Doggy Bone DNA
FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
Patents
Patent Holdings by Manufacturer
Clinical Trials
Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

Segmentation Breakdown
Market Breakdown by Product Type
Market Breakdown by End User
Research Institutes
Pharmaceutical and Biopharmaceutical Companies
Market Breakdown by Application
Cancer
Genetic Disorders
Infectious Diseases
Cardiovascular Diseases
Other Diseases
Geographic Breakdown
Market Breakdown by Region
North America
Latin America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Industry Scenario
Company Shares
Competitive Landscape among Companies
Competitive Landscape in Viral Vectors
Competitive Landscape in Plasmid DNA

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

Introduction
Environmental Factors
Social Factors
Governance Factors
ESG Performance among Major Companies
ESG Performance of Select Companies
Lonza: ESG Performance
Thermo Fisher Scientific: ESG Performance
Conclusion

Chapter 8 Appendix

Research Methodology
Acronyms
References
Company Profiles
AGILENT TECHNOLOGIES INC.
BLUEBIRD BIO INC.
CATALENT INC.
DANAHER CORP.
FUJIFILM HOLDINGS CORP.
GENSCRIPT
GILEAD SCIENCES INC.
LONZA
NOVARTIS AG
OXFORD BIOMEDICA PLC
PLASMIDFACTORY GMBH
REGENXBIO INC.
THERMO FISHER SCIENTIFIC INC.
VGXI INC.

Product Code: BIO192B

List of Tables

Summary Table : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 1 : Global Incidence of All Cancers, by WHO Region, 2022-2050
Table 2 : Global Incidence of Leukemia, by WHO Region, 2022-2050
Table 3 : Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 4 : Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 5 : Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050
Table 6 : Patents Held by Oxford Biomedica, 2021-Present
Table 7 : Selected Patents Held by Lonza, 2021-Present
Table 8 : Patents Held by Regenxbio, 2021-Present
Table 9 : Selected Clinical Trials, by Viral Vector Type
Table 10 : Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
Table 11 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 12 : Global Market for Plasmid DNA Technology, by Region, Through 2028
Table 13 : Global Market for Viral Vector Technology, by Region, Through 2028
Table 14 : Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028
Table 15 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028
Table 16 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028
Table 17 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028
Table 18 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028
Table 19 : Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
Table 20 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 21 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028
Table 22 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 23 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 24 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 25 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 26 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 27 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 28 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 29 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 30 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 31 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 32 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028
Table 33 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 34 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 35 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 36 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 37 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 38 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 39 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 40 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 41 : RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 42 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 43 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028
Table 44 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 45 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 46 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 47 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 48 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 49 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 50 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 51 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 52 : RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 53 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 54 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028
Table 55 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 56 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 57 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 58 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 59 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 60 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 61 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 62 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 63 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 64 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 65 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028
Table 66 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 67 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 68 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 69 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 70 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 71 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 72 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 73 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028
Table 74 : RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 75 : Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
Table 76 : North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 77 : North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 78 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 79 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 80 : European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 81 : European Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 82 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 83 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 84 : RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 85 : ESG Rankings of Major Companies, 2024*
Table 86 : Lonza: ESG Performance
Table 87 : Thermo Fisher Scientific Inc.: ESG Performance
Table 88 : Acronyms Used in This Report
Table 89 : Agilent Technologies Inc.: Company Snapshot
Table 90 : Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022
Table 91 : Agilent Technologies Inc.: Product Portfolio
Table 92 : Agilent Technologies Inc.: News/Key Developments, 2023
Table 93 : Bluebird Bio Inc.: Company Snapshot
Table 94 : Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
Table 95 : Bluebird Bio Inc.: Product Portfolio
Table 96 : Bluebird Bio Inc.: Key News/Developments, 2022
Table 97 : Catalent Inc.: Company Snapshot
Table 98 : Catalent Inc.: Financial Performance, FY 2021 and 2022
Table 99 : Catalent Inc.: Product Portfolio
Table 100 : Catalent Inc.: Key News/Developments, 2021-2024
Table 101 : Danaher Corp.: Company Snapshot
Table 102 : Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 103 : Danaher Corp.: Product Portfolio
Table 104 : Danaher Corp.: News/Key Developments, 2022
Table 105 : Fujifilm Holdings Corp.: Company Snapshot
Table 106 : Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022
Table 107 : Fujifilm Holdings Corp.: Product Portfolio
Table 108 : Fujifilm Holdings Corp.: News/Key Developments, 2022
Table 109 : GenScript: Company Snapshot
Table 110 : GenScript: Financial Performance, FY 2021 and 2022
Table 111 : GenScript: Product Portfolio
Table 112 : GenScript: News/Key Developments, 2023
Table 113 : Gilead Sciences Inc.: Company Snapshot
Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
Table 115 : Gilead Sciences Inc.: Product Portfolio
Table 116 : Gilead Sciences Inc.: News/Key Developments, FY 2021-2022
Table 117 : Lonza: Company Snapshot
Table 118 : Lonza: Financial Performance, FY 2021 and 2022
Table 119 : Lonza: Product Portfolio
Table 120 : Lonza: News/Key Developments, FY 2022
Table 121 : Novartis AG: Company Snapshot
Table 122 : Novartis AG: Financial Performance, FY 2021 and 2022
Table 123 : Novartis AG: Product Portfolio
Table 124 : Novartis AG: News/Key Developments, FY 2022
Table 125 : Oxford Biomedica Plc: Company Snapshot
Table 126 : Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
Table 127 : Oxford Biomedica Plc: Product Portfolio
Table 128 : Oxford Biomedica Plc: News/Key Developments, FY 2022
Table 129 : PlasmidFactory GmbH: Company Snapshot
Table 130 : PlasmidFactory GmbH: Product Portfolio
Table 131 : Regenxbio Inc.: Company Snapshot
Table 132 : Regenxbio Inc: Financial Performance, FY 2021 and 2022
Table 133 : Regenxbio Inc: Product Portfolio
Table 134 : Regenxbio Inc.: News/Key Developments, FY 2022
Table 135 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 136 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
Table 137 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 138 : VGXI Inc.: Company Snapshot
Table 139 : VGXI Inc.: Product Portfolio

List of Figures

Summary Figure A : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
Summary Figure B : Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022
Figure 1 : Viral Vector and Plasmid DNA Technologies: Market Dynamics
Figure 2 : Approved Cell and Gene Therapy Product Count, 2003 to the Present
Figure 3 : Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies
Figure 4 : Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022
Figure 5 : Global Company Market Shares of Viral Vectors, 2022
Figure 6 : Global Company Market Shares of Plasmid DNA, 2022
Figure 7 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022
Figure 8 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2022
Figure 9 : Catalent Inc.: Revenue Share, by Business Unit, FY 2022
Figure 10 : Catalent Inc.: Revenue Share, by Country/Region, FY 2022
Figure 11 : Danaher Corp.: Revenue Share, by Business Unit, FY 2022
Figure 12 : Danaher Corp.: Revenue Share, by Country/Region, FY 2022
Figure 13 : Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022
Figure 14 : Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022
Figure 15 : GenScript: Revenue Share, by Business Unit, FY 2022
Figure 16 : GenScript: Revenue Share, by Country/Region, FY 2022
Figure 17 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022
Figure 18 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022
Figure 19 : Lonza: Revenue Share, by Business Unit, FY 2022
Figure 20 : Lonza: Revenue Share, by Country/Region, FY 2022
Figure 21 : Novartis AG: Revenue Share, by Business Unit, FY 2022
Figure 22 : Novartis AG: Revenue Share, by Country/Region, FY 2022
Figure 23 : Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022
Figure 24 : Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022
Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022
Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022

Viral Vector and Plasmid DNA: Technologies and Global Markets

Description

Table of Contents

List of Tables

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Emerging Technologies and Developments

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

Chapter 6 Competitive Intelligence

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

Chapter 8 Appendix

List of Tables

List of Figures